Next steps: sequencing therapies in metastatic kidney cancer in the contemporary era
AL Schmidt, AL Tabakin, EA Singer… - American Society of …, 2021 - ascopubs.org
Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune
checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 …
checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 …
Analysis of single circulating tumor cells in renal cell carcinoma reveals phenotypic heterogeneity and genomic alterations related to progression
Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response
prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal …
prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal …
[HTML][HTML] KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
The association between kidney disease and cancer is multifaceted and complex. Persons
with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer …
with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer …
Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values
JJ Adashek, G Genovese, NM Tannir… - Cancer treatment and …, 2020 - Elsevier
The therapeutic options for advanced or metastatic renal cell carcinoma (mRCC) have
drastically evolved over the past 20 years. High-dose interleukin-2 (HD IL-2), which led to …
drastically evolved over the past 20 years. High-dose interleukin-2 (HD IL-2), which led to …
Characterization of patients with metastatic renal cell carcinoma undergoing deferred, upfront, or no cytoreductive nephrectomy in the era of combination …
Background The role of cytoreductive nephrectomy (CN) has not yet been well characterized
in the era of combination immunotherapy. Objective To evaluate characteristics and …
in the era of combination immunotherapy. Objective To evaluate characteristics and …
A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical …
L Gu, H Li, Z Wang, B Wang, Q Huang, X Lyu… - Cancer Treatment …, 2018 - Elsevier
Background There remain discrepancies over the factors that influence oncologic outcomes
after radical nephrectomy with thrombectomy (RNTE). To assess significant predictors of …
after radical nephrectomy with thrombectomy (RNTE). To assess significant predictors of …
Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic
R Dotzauer, K Böhm, MP Brandt, P Sparwasser… - World journal of …, 2021 - Springer
Objectives While the coronavirus disease 2019 (COVID-19) pandemic captures healthcare
resources worldwide, data on the impact of prioritization strategies in urology during …
resources worldwide, data on the impact of prioritization strategies in urology during …
Surgical and focal treatment for metastatic renal cell carcinoma: A literature review
S Naito, T Kato, N Tsuchiya - International Journal of Urology, 2022 - Wiley Online Library
Accompanied by the development of systemic therapy for metastatic renal cell carcinoma,
the concept of focal treatment, including surgical treatment, has been changing. Although …
the concept of focal treatment, including surgical treatment, has been changing. Although …
Long non-coding RNAs as novel biomarkers in the clinical management of papillary renal cell carcinoma patients: a promise or a pledge?
F Trevisani, M Floris, R Vago, R Minnei, A Cinque - Cells, 2022 - mdpi.com
Papillary renal cell carcinoma (pRCC) represents the second most common subtype of renal
cell carcinoma, following clear cell carcinoma and accounting for 10–15% of cases. For …
cell carcinoma, following clear cell carcinoma and accounting for 10–15% of cases. For …
Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma
C Zhang, X Lu, J Huang, H He, L Chen… - Clinical and …, 2021 - Wiley Online Library
Aberrant epigenetic reprogramming represents a hallmark of renal cell carcinoma (RCC)
tumorigenesis and progression. Whether there existed other epigenetic vulnerabilities that …
tumorigenesis and progression. Whether there existed other epigenetic vulnerabilities that …